BioValues retweeted
*SANOFI IS SAID TO WEIGH TAKEOVER OF US DRUGMAKER INSMED $INSM
BioValues retweeted
$PEPG Ra Capital from offering sec.gov/Archives/edgar/data/…
$PEPG
Guggenheim raised the firm's price target on PepGen to $15 from $7 and keeps a Buy rating on the shares. The firm, which is "encouraged" by the transparency and clarity on individual patient level outcomes in the PGN-EDODM1 10 mg/kg data, says a bolstered balance sheet positions the company well to execute on its registrational study during 2027.
BioValues retweeted
Cantor reiterated an Overweight rating on $LXEO and said--One-time gene therapy LX2020's showing of 80% mean reduction in non-sustained ventricular tachycardia (NSVT) far exceeds the ~30% provided by current pharmacological standard of care and what we believe to be the market's bar-and significantly derisks eventual accelerated approval as we anticipate this measure to be the primary endpoint of the upcoming pivotal study.
[TYNA RCKT [BIIB LRMR PTCT DSGN SLDB NBIX VYGR]]
Safety with high dose LX2020 presented no surprises.
Together with LX2006, in pivotal development for Friedreich ataxia, we see LXEO as possessing two assets that each offer line of sight to $1B+ sales potential for unmet patient populations that are genetically-defined and clinically-identifiable.
We had already viewed the shares as trading at a significant discount to the FA opportunity alone; today's news appears to put that discount into even sharper relief. We are buyers.
Cantor reiterated $LXEO Overweight-$35 and said that it Sees a High PoS for the FA Pivotal Trial (2H27 guide) hitting on Deepened Conviction.
[BIIB LRMR PTCT]
Cantor said in its note:
Topline data from SUNRISE-FA 2, the pivotal trial evaluating LX2006 (AAVrh10-based gene therapy) for Friedreich's ataxia (FA), are guided for 2H27 and represent a major upcoming catalyst for LXEO shares.
Investor debate has centered on the PoS of this trial, particularly given that the trial is powered around a >= 15% LVMI treatment effect, while a ≥10% threshold is considered clinically meaningful.
Lexeo has conducted analyses supporting a ~99% probability of achieving ≥15% effect size informed by the Phase 1/2 data and additional natural-history and CLARITY-FA data not available to the public.
This has prompted us to go a step further and independently assess the trial's PoS and deepen our conviction ahead of the readout.
The punchline is that our analysis also supports a high PoS for the pivotal trial, increasing our conviction ahead of this major catalyst.
BioValues retweeted
$LXEO large unmet need here ir.lexeotx.com/static-files/…
$LXEO Participants in high-dose cohorts achieved 80% mean reduction in non-sustained ventricular tachycardia and 44% mean reduction in premature ventricular contractions at latest assessment
LX2020 generally well tolerated across 10 participants with no clinically significant complement activation
U.S. Food and Drug Administration open to guideline-defined non-sustained ventricular tachycardia as a primary surrogate endpoint to support potential accelerated approval of LX2020
Cash, cash equivalents and investments of $219.1 million expected to provide operational runway into 2028
Company to host webcast today at 8:00 AM ET
BioValues retweeted
$LXEO High-dose PKP2-ACM therapy resulted in 80% reduction in NSVT (!!!), where 20-30% represents current therapy and 35-40% clinically meaningful for their gene therapy. Strong result showing meaningful deepening, just as management suspected it would 💪
ir.lexeotx.com/news-releases…
BioValues retweeted
Cantor reiterated $LXEO Overweight-$35 and said that it Sees a High PoS for the FA Pivotal Trial (2H27 guide) hitting on Deepened Conviction.
[BIIB LRMR PTCT]
Cantor said in its note:
Topline data from SUNRISE-FA 2, the pivotal trial evaluating LX2006 (AAVrh10-based gene therapy) for Friedreich's ataxia (FA), are guided for 2H27 and represent a major upcoming catalyst for LXEO shares.
Investor debate has centered on the PoS of this trial, particularly given that the trial is powered around a >= 15% LVMI treatment effect, while a ≥10% threshold is considered clinically meaningful.
Lexeo has conducted analyses supporting a ~99% probability of achieving ≥15% effect size informed by the Phase 1/2 data and additional natural-history and CLARITY-FA data not available to the public.
This has prompted us to go a step further and independently assess the trial's PoS and deepen our conviction ahead of the readout.
The punchline is that our analysis also supports a high PoS for the pivotal trial, increasing our conviction ahead of this major catalyst.
Oppenheimer reiterated $LXEO Outperform-$20 and said--Updated LX2006 data strengthen our conviction in this candidate's market potential in Friedreich ataxia (FA).
[BIIB LRMR PTCT SLDB [TNYA RCKT]]
The neurologic efficacy signal has been extended with a 4.26-point mFARS advantage versus propensity-matched natural-history controls over two years and greater than four-point improvement from baseline in participants followed for three years.
Alongside sustained cardiac improvements, these findings increasingly support a differentiated, multisystem treatment profile over merely a cardiomyopathy-only proposition.
While small, open-label datasets require confirmation, we believe the growing consistency and durability of benefit strengthen LX2006's investment case and warrant greater recognition of its potential value.
LX2020's reveal in PKP2-ACM remains on track for this quarter-which we believe could raise this program's visibility among investors given $1B+ peak sales potential.
We see at compelling entry point in LXEO stock at current levels.
BioValues retweeted
$PEPG sure, they will raise, but demand will be there. $300M market cap in premarket. Novartis shelled out $10B+ for much worse p2 data.
BioValues retweeted
$PEPG Home run data - 46.5% best-in-disease mean splicing, functional improvements (vHOT, 10MWRT), clean safety. Let's go! 💪🔥
investors.pepgen.com/news-re…
BioValues retweeted
$PEPG Announces Positive Phase 2 FREEDOM2-DM1 10 mg/kg Results Demonstrating Highest Reported Splicing Correction and Improvements Across Multiple Functional Measures
businesswire.com/news/home/2…
BioValues retweeted
First use of CAR-NK in myositis
Off-the-shelf CAR NK are more accessible, less onerous... unknown if equally effective
Early myositsi data; NKX019 was studied in 6 pts: 4 DM, 1 antisynthetase syndrome, 1 IMNM
Moderate-to-major TIS responses and no CRS or ICANS reported
Median f/u only 2.5 months & no denominator
@RheumNow #ACR26 Ab#0903
BioValues retweeted
$NKTX Data Monday!
BioValues retweeted
$NKTX New Job Posted Today - Senior Director/Executive Director, Clinical Data Management
Prepare NKX019’s DM infrastructure for potential pivotal trials and a BLA, establish readiness before pivotal studies begin, and recruit/manage staff.
Require someone with previous pivotal-study and marketing-application experience
Upcoming presentations are Nov 8: myositis; Nov 9: #Ssc; Nov 11: overall safety
job-boards.greenhouse.io/nka…
$NKTX New job posted - Associate General Counsel
“Advise... including license, collaboration, and strategic vendor agreements”
“Support capital markets, financing, and strategic transactions, including due diligence and transaction documents”
job-boards.greenhouse.io/nka…
BioValues retweeted
$LXEO Cantor view LX2020 under-appreciated asset in story, believe the Street is assigning little value to both programs today.
estimate only ~30% of FA & ~10% of the PKP2-ACM opportunity are currently reflected in the stock.If the upcoming PKP2 data are strong, coupled with greater clarity on the FDA’s expectations, could meaningfully de-risk the program and support ~50% upside in the stock.
$LXEO educational investor event (10/21) focused on the clinical significance of arrhythmia endpoints in PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM). ir.lexeotx.com/static-files/…
BioValues retweeted
Replying to @HOThomasWPhelps @scowl731
BioValues retweeted
Replying to @scowl731
Safety and durability are the key questions always in these. So far NKX-019 shown to be safe, but they do use fludarabine as well so will have to understand that. NKX-019 is engineered CD19-directed CAR-NK cells w/ membrane bound IL-15 could aide in both durability/persistence and safety.
Nkarta discussing safety in separate presentation in a couple weeks time as a key differentiating factor.





















